Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Background Repeat hospitalizations of patients with atherosclerosis represent a
considerable burden on the health care system. We sought to determine whether …

Background Many clinical trials have evaluated the benefit of long-term use of antiplatelet
drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been …

The recent CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events)
compared clopidogrel with aspirin in reducing the risk of vascular events in 19 185 patients …

Atherothrombotic coronary artery disease is the single most common cause of death
worldwide and a growing public health problem. Platelets play a central role in the …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …